HealthPlus Retail Group — Implementation Roadmap
The phased implementation roadmap and key milestones from capitalisation and infrastructure build to the 450-store national rollout.
Section 9 · Business Plan
Implementation Roadmap
The phased implementation roadmap and key milestones from capitalisation and infrastructure build to the 450-store national rollout.
9.1 Roadmap Overview
The implementation programme is structured across five
sequential-overlapping phases spanning 72 months from financial close.
Each phase is gated by quantitative criteria — store count, revenue
run-rate, EBITDA margin, and balance-sheet leverage — that govern access
to subsequent capital tranches. This staged-release model protects
investors against execution slippage while preserving capital
efficiency.
Failure to meet defined gate criteria triggers a board-level review and,
if material, a re-pricing of the next tranche.
9.2 Master Gantt Chart
Figure 9.1 presents the consolidated 72-month Gantt chart. Five
phases — Foundation, Pilot, National Rollout, Scale & Densify, and
Expansion — overlap deliberately to balance speed-to-market against
operational stability. Critical-path dependencies are flagged against
site-availability and pharmacist-supply assumptions.
9.3 Phase Detail
9.3.1 Phase 1 — Foundation (Months 0–6)
Foundation establishes the institutional, regulatory and
infrastructural backbone of the business. No revenue is generated in
this phase; capital deployment is concentrated on people, systems, and
licences.
9.3.2 Phase 2 — Pilot (Months 6–18)
Pilot validates the unit economics of the operating model under live
conditions in two metro markets (Gauteng and Western Cape). Thirty
stores are opened; the loyalty programme and digital platform are
launched; private-label production is initiated through contract
manufacturers. Gate criteria for Phase 3 release are tested at month
18.
9.3.3 Phase 3 — National Rollout (Months 18–36)
National Rollout extends the operating model to all nine provinces.
Store openings accelerate to 70+ per year; the second DC (KwaZulu-Natal)
goes live; the manufacturing facility (Gauteng) commences commissioning.
EBITDA breakeven is achieved in late Y2.
9.3.4 Phase 4 — Scale & Densify (Months 36–54)
Scale & Densify focuses on geographic densification (filling
white-space within existing metros) and category extension (premium
beauty, clinical services, infant nutrition). The third DC (Western
Cape) is commissioned. The business achieves investment-grade unit
economics and prepares the listing readiness work-stream.
9.3.5 Phase 5 — Expansion & Listing (Months 54–72)
Expansion completes the Y5 store target of 450, executes the JSE
listing, and initiates the SADC expansion plan (Botswana, Namibia,
Zambia, Zimbabwe, Mozambique) via a separate investment vehicle. The
listing provides the primary equity exit route for early investors and
recapitalises the balance sheet for the next growth phase.
9.4 Critical Milestones
| # | Milestone | Target Month | Phase | Owner |
|---|---|---|---|---|
| M1 | Financial close & equity drawdown | M0 | Foundation | CEO / CFO |
| M2 | SAPC pharmacy ownership licence | M3 | Foundation | CPO |
| M3 | First store opened (Sandton) | M6 | Pilot | COO |
| M4 | PlusOne app live | M9 | Pilot | CTO / CMO |
| M5 | Phase 2 → 3 gate review | M18 | Pilot | Board |
| M6 | 100th store opened | M24 | Rollout | COO |
| M7 | EBITDA breakeven (monthly) | M22 | Rollout | CFO |
| M8 | Manufacturing facility commercial | M30 | Rollout | COO |
| M9 | 200th store opened | M34 | Rollout | COO |
| M10 | Phase 3 → 4 gate review | M36 | Rollout | Board |
| M11 | 300th store opened | M48 | Scale | COO |
| M12 | JSE sponsor appointed | M48 | Scale | CFO |
| M13 | JSE listing executed | M60–66 | Expansion | CEO / CFO |
| M14 | 450th store opened | M72 | Expansion | COO |
| M15 | First SADC store opened | M66 | Expansion | CEO |
Table 9.1 — Critical milestone register
9.5 Critical Path Risks & Mitigations
Three dependencies dominate the critical path: SAPC licensing
throughput, pharmacist supply, and prime retail-site availability. Each
is actively managed via dedicated work-streams.
| Critical-Path Risk | Impact if Slip | Mitigation | Buffer |
|---|---|---|---|
| SAPC licensing delays | +3–6 months on rollout | Pre-engage SAPC; specialist regulatory firm; phased filings | 90 days |
| Pharmacist recruitment | Cap on store openings | Bursary pipeline; SADC recruitment; PA career ladder | 60 days |
| Prime site availability | Sub-optimal store mix | Pre-signed MOUs with 4 mall REITs covering 280 sites | 120 days |
| ERP/POS go-live | +30–60 days on store opens | Phased deployment; parallel-run protocol; 24/7 vendor SLA | 45 days |
| DC commissioning | Service-level breaches | Stage-gated commissioning; 3PL backstop contracts | 60 days |
Table 9.2 — Critical-path risk register
A dedicated Programme Management Office (PMO), reporting to the COO
and the Board, maintains the master schedule, tracks 240+ work-streams,
and produces a monthly programme dashboard. The PMO operates on a
stage-gate methodology aligned to PMI standards, ensuring no phase
advances without documented gate approval.
Confidential — this business plan is provided to prospective investors and lenders for evaluation purposes only and may not be reproduced or distributed without the written consent of HealthPlus Retail Group (Pty) Ltd.